Lincoln Pharmaceuticals share news, announcements and annual reports
NSE: LINCOLNBSE: 531633Pharmaceuticals & BiotechnologySmall Cap
Lincoln Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1996 on BSE, Dec 2015 on NSE
Last close ₹558.10up ₹8.05 (1.46%)BSE ₹557.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹550.05.
28 Oct: open ₹541.00, high ₹560.00, low ₹532.00
52-week range of traded prices to 28 Oct 2026
₹440.00Low, 28 Jan 2026₹770.00High, 27 May 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,118 Cr1,389th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.59
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.32%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 47,20541.0% delivered
Lincoln Pharmaceuticals share news and announcements
352 announcements, routine notices left out, newest first. Page 2 of 8.
Mar 2025
4 Mar · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2025
13 Feb · Results
Jan 2025
3 Jan · General Updates
Dec 2024
11 Dec · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.6 Dec · Legal
The exchange asked on 6 Dec 2024
6 Dec · Legal
The exchange asked on 3 Dec 2024
Nov 2024
14 Nov · Results
Oct 2024
Sep 2024
Aug 2024
8 Aug · Results
Jul 2024
May 2024
16 May · Results
15 May · Analysts
Apr 2024
9 Apr · Meeting
1 Apr · Management
Mar 2024
30 Mar · Management
Feb 2024
8 Feb · Results
Jan 2024
11 Jan · Legal
The exchange asked on 11 Jan 2024
Nov 2023
2 Nov · Results
Oct 2023
Sep 2023
30 Sep · Meeting
Aug 2023